文献速递冠心病外科

无心脏外科现场支持中心的多支冠脉病变患者中期结局

Midterm outcomes of patients with multivessel disease treated at centers with and without on-site cardiac surgery services.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-05-30

该前瞻性注册研究纳入以色列22家可行冠脉造影和经皮冠脉介入的医院共1063例多支冠脉病变患者,比较有无现场心脏外科服务对中期结局的影响。结果显示有现场心脏外科服务的中心6年生存概率更高(85.1% vs 81.3%,P = .047),且冠脉搭桥(vs 经皮冠脉介入)的生存优势仅见于有心脏外科服务的中心。

要点

  • 有现场心脏外科服务的中心6年生存概率高于无此类服务的中心(85.1% vs 81.3%,P = .047)。
  • 冠脉搭桥相较于经皮冠脉介入的生存优势仅见于有心脏外科服务的中心(89.9% vs 81.5%,P = .004)。
  • 无现场心脏外科服务的中心中两种血运重建方式生存无差异(81.8% vs 81.1%,P = .9)。

核心结论

  • 无现场心脏外科服务的中心对多支冠脉病变患者实施指南推荐的冠脉搭桥比例较低,且结局较差。
  • 研究提示即使独立介入心脏病学中心也应强制执行心脏团队决策。

研究设计与样本

  • 前瞻性注册研究,纳入2013年1月至4月以色列全部22家可行冠脉造影和经皮冠脉介入的医院。
  • 共纳入1063例连续多支冠脉病变患者。

主要发现

  • 576例(54%)收治于有现场心脏外科服务的中心,487例(46%)收治于无现场心脏外科服务的中心。
  • 有心脏外科服务的中心男性比例更高(82% vs 77%,P = .026),入院前服用阿司匹林比例更高(75% vs 67%,P = .008)。
  • 两组平均SYNTAX评分相似(22.5 ± 9.6 vs 22.2 ± 10,P = .680)。
  • 有现场心脏外科服务的中心6年生存概率更高(85.1% vs 81.3%,P = .047)。
  • 在有心脏外科服务的中心,冠脉搭桥相较于经皮冠脉介入有生存优势(89.9% vs 81.5%,P = .004);无现场心脏外科服务的中心中两种方式无差异(81.8% vs 81.1%,P = .9)。

临床怎么用

  • 多支冠脉病变患者应通过心脏团队评估血运重建策略,尤其在无现场心脏外科服务的中心。
  • 无现场心脏外科服务的中心需关注冠脉搭桥指南推荐干预的实施情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The last decade has witnessed an increased number of stand-alone interventional cardiology units due to the consolidation of cardiac surgery services. We aimed to explore the impact of a heart team on the midterm outcomes of patients with multivessel coronary artery disease. METHODS: This prospective registry included 1063 consecutive patients with multivessel disease enrolled between January and April 2013 from all 22 hospitals in Israel that perform coronary angiography and percutaneous coronary intervention, with or without on-site cardiac surgery services. RESULTS: Of the 1063 patients, 576 (54%) and 487 (46%) were admitted to centers with or without on-site cardiac surgery services, respectively. Centers with cardiac surgery services compared with those without had more male patients (82% vs 77%, P = .026) and more patients who were taking aspirin (75% vs 67%, P = .008) before admission. Other characteristics were similar between the groups, including mean SYNTAX score (22.5 ± 9.6 vs 22.2 ± 10, P = .680). Late outcomes revealed a higher 6-year survival probability in centers with on-site cardiac surgery services (85.1% vs 81.3%, P = .047). Although coronary artery bypass grafting (vs percutaneous coronary intervention) was associated with a survival advantage among patients from hospitals with cardiac surgery services (89.9% vs 81.5%, P = .004), in the absence of on-site cardiac surgery services there were no differences between the 2 revascularization approaches (81.8% vs 81.1%, P = .9). CONCLUSIONS: Patients with multivessel coronary artery disease treated in centers without on-site cardiac surgery services receive a lower rate of appropriate guideline-based intervention with coronary artery bypass grafting, which is associated with less favorable outcomes. These findings suggest that a heart-team approach should be mandatory even in centers with stand-alone interventional cardiology units.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ram E, Raanani E, Klempfner R, et al. Midterm outcomes of patients with multivessel disease treated at centers with and without on-site cardiac surgery services. J Thorac Cardiovasc Surg. 2020. PMID: 32711976. doi:10.1016/j.jtcvs.2020.04.170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。